Pulsatile high-dose treatment with antiangiogenic tyrosine kinase inhibitors improves clinical antitumor activity
Sign Up to like & getrecommendations! Published in 2017 at "Angiogenesis"
DOI: 10.1007/s10456-017-9555-8
Abstract: Angiogenesis comprises one of the core hallmarks of cancer, essential for tumor establishment and growth. Elucidating the components of the angiogenic molecular pathway led to the identification of the crucial signaling axis of vascular endothelial… read more here.
Keywords: treatment; tkis; activity; tyrosine kinase ... See more keywords
Hype or hope - Can combination therapies with third-generation EGFR-TKIs help overcome acquired resistance and improve outcomes in EGFR-mutant advanced/metastatic NSCLC?
Sign Up to like & getrecommendations! Published in 2021 at "Critical reviews in oncology/hematology"
DOI: 10.1016/j.critrevonc.2021.103454
Abstract: Three generations of epidermal growth factor receptor - tyrosine kinase inhibitors (EGFR-TKIs) have been developed for treating advanced/metastatic non-small cell lung cancer (NSCLC) patients harboring EGFR-activating mutations, while a fourth generation is undergoing preclinical assessment.… read more here.
Keywords: advanced metastatic; combination; egfr tkis; resistance ... See more keywords
Application of liquid biopsy-based targeted capture sequencing analysis to improve the precision treatment of non-small cell lung cancer by tyrosine kinase inhibitors
Sign Up to like & getrecommendations! Published in 2022 at "BMJ Open Respiratory Research"
DOI: 10.1136/bmjresp-2021-001154
Abstract: Background Targeted therapy of patients with non-small cell lung cancer (NSCLC) who harbour sensitising mutations by tyrosine kinase inhibitors (TKIs) has been found more effective than traditional chemotherapies. However, target genes status (eg, epidermal growth… read more here.
Keywords: cell; capture sequencing; tkis; treatment ... See more keywords
Abstract 4594: EGFR PACC mutations occur more frequently as compound mutations with better responses to EGFR TKIs
Sign Up to like & getrecommendations! Published in 2025 at "Cancer Research"
DOI: 10.1158/1538-7445.am2025-4594
Abstract: EGFR mutations are key oncogenic drivers in NSCLC and can occur either as single or compound mutations. The frequency of classical (Ex19del and L858R) and non-classical PACC mutations in single and compound forms is not… read more here.
Keywords: pacc mutations; gen; tkis; compound ... See more keywords
Abstract 6000: Vabametkib plus lazertinib shows promising antitumor activity in advanced NSCLC with MET amplification resistant to 3rd-gen EGFR-TKIs
Sign Up to like & getrecommendations! Published in 2025 at "Cancer Research"
DOI: 10.1158/1538-7445.am2025-6000
Abstract: MET amplification (METamp) can emerge as a bypass mechanism of resistance to EGFR tyrosine kinase inhibitors (TKIs), occurring in up to 26% of patients with EGFR TKI-resistant EGFR-mutant non-small cell lung cancer (NSCLC). ABN401 (vabametkib),… read more here.
Keywords: egfr; tkis; 3rd gen; vabametkib ... See more keywords
Tyrosine Kinase Inhibitor–Associated Platelet Dysfunction: Does This Need to Have a Significant Clinical Impact?
Sign Up to like & getrecommendations! Published in 2019 at "Clinical and Applied Thrombosis/Hemostasis"
DOI: 10.1177/1076029619866925
Abstract: The management of chronic myeloid leukemia (CML) entirely changed after the emergence of tyrosine kinase inhibitors (TKIs). In the era of TKIs, the 10-year overall survival now exceeds 80%, and the prevalence of patients receiving… read more here.
Keywords: platelet function; platelet functions; platelet dysfunction; tkis ... See more keywords
ABL Tyrosine Kinase Inhibitors (TKIs) Are Associated with Increased Rho-Associated Kinase (ROCK) Activity That May Contribute to Vascular Toxicity in Patients with Chronic Myeloid Leukemia (CML)
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-111201
Abstract: Introduction The use of 2nd or 3rd generation ABL TKIs in patients with CML is associated with vascular toxicity, including peripheral arterial occlusive disease and cardiovascular and cerebrovascular events. However, Imatinib, a 1st generation TKI,… read more here.
Keywords: rock activity; patients receiving; leukocyte rock; tkis ... See more keywords
Chronic myeloid leukaemia in the pregnancy: Experience at a university hospital in Paraguay
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-7299
Abstract: Introduction Chronic myeloid leukaemia (CML) is defined by the presence of the BCR::ABL1 oncogene, resulting from a translocation between chromosomes 9 and 22. This translocation, fuses parts of the BCR and ABL1 genes, creating a… read more here.
Keywords: myeloid leukaemia; age; pregnancy; tkis ... See more keywords
Pulmonary complications of tyrosine kinase inhibitors in myeloproliferative disorders
Sign Up to like & getrecommendations! Published in 2020 at "European Respiratory Journal"
DOI: 10.1183/13993003.02653-2020
Abstract: Life has changed for patients with chronic myeloid leukaemia (CML) since the introduction of breakpoint cluster region–Abelson (Bcr-Abl) tyrosine kinase inhibitors (TKIs) in the late 1990s. Before the era of the TKIs began, the 5-year… read more here.
Keywords: kinase inhibitors; pulmonary complications; bcr abl; tkis ... See more keywords
Oncologists’ perspectives on challenges using chemotherapy, immune checkpoint inhibitors, and targeted kinase inhibitors for metastatic cancer.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.16_suppl.1548
Abstract: 1548 Background: Compared to cytotoxic chemotherapies, the standard of care for metastatic cancers for decades, use of immune checkpoint inhibitors (ICI) and targeted kinase inhibitors (TKI) has rapidly expanded with evolving indications for patients with… read more here.
Keywords: oncology; challenges using; chemotherapy; tkis ... See more keywords
Vebreltinib plus PLB1004 in EGFR-mutated NSCLC with acquired MET amplification or overexpression after failure on EGFR-TKI treatment: A phase Ib/II study.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.16_suppl.8632
Abstract: 8632 Background: MET amplification (METamp) or overexpression (METov) is the most common “off-target” mechanism that drives resistance to EGFR-TKIs. Vebreltinib is a potent and selective c-Met inhibitor, while PLB1004 is an oral, potent, irreversible, and… read more here.
Keywords: egfr; metamp; generation; egfr tkis ... See more keywords